A simple and high-throughput luciferase immunosorbent assay for both qualitative and semi-quantitative detection of anti-HIV-1 antibodies

2019 ◽  
Vol 263 ◽  
pp. 9-15 ◽  
Author(s):  
Haiying Wang ◽  
Qundi Cai ◽  
Yuanhao Liang ◽  
Jingwei Shui ◽  
Shixing Tang
2006 ◽  
Vol 43 (13) ◽  
pp. 2119-2123 ◽  
Author(s):  
Rosa María Ferraz ◽  
Anna Arís ◽  
Miguel Angel Martínez ◽  
Antonio Villaverde

2003 ◽  
Vol 8 (6) ◽  
pp. 685-693 ◽  
Author(s):  
Shuwen Liu ◽  
Louise Boyer-Chatenet ◽  
Hong Lu ◽  
Shibo Jiang

The human immuno deficiency virus type 1 (HIV-1) envelope glycoprotein gp41 plays animportant role in the virus entry. During the process of fusion between the viral and target cell membranes, the N-and C-terminal heptad repeat (HR) regions of the gp41 extracellular domain associate to form a 6-helical bundle, corresponding to the fusion-active gp41 core. Any compound that blocks the gp41 6-helix bundle formation between the N- and C-peptides, which are derived from the N- and C-terminal HR regions, respectively, may inhibit HIV-1 mediated membrane fusion. Based on this principle, we previously established a sandwich enzyme-linked immunosorbent assay (ELISA) for drug screening by using the N-peptide N36 and the C-peptide C34 and a monoclonal antibody (NC-1) which specifically recognizes the gp41 6-helix bundle. In the present study, a fluorescence-linked immunosorbent assay (FLISA) was developed by using fluorescein isothiocyanate (FITC)-conjugated C34 to replace C34 and by directly detecting fluorescence intensity instead of more complicated enzymatic reaction. Compared with the sandwich ELISA, this FLISA has similar sensitivity and specificity, but it is much more rapid, economic and convenient. Using an Integrated Robotic Sample Processing System, this assay has been applied for high-throughput screening of organic compounds on a large scale for HIV-1 fusion inhibitors targeting gp41.


2015 ◽  
Vol 13 (6) ◽  
pp. 1792-1799 ◽  
Author(s):  
Fudi Zhong ◽  
Guannan Geng ◽  
Bing Chen ◽  
Ting Pan ◽  
Qianwen Li ◽  
...  

A benzenesulfonamide quinoline compound with potent anti-HIV-1 replication activity and low toxicity by targeting HIV-1 Rev protein was identified with high-throughput screening and SAR studies.


1989 ◽  
Vol 61 (01) ◽  
pp. 081-085 ◽  
Author(s):  
Simon Panzer ◽  
Christoph Stain ◽  
Hubert Hartl ◽  
Robert Dudczak ◽  
Klaus Lechner

SummaryLevels of anticardiolipin antibodies (ACA) were measured in 55 patients with haemophilia A in serum samples obtained in 1983 and in 1987. Twenty-one patients were negative for anti HIV-1 antibodies in 1983 and remained negative in 1987; 34 patients had anti HIV-1 antibodies in 1983; 17 of these latter patients remained asymptomatic, whereas 17 patients developed ARC or AIDS during the 4 years follow-up. Thirteen anti HIV-1 negative patients had elevated ACA levels in 1983; subsequently, a significant decrease was observed in all these subjects (p <0.001). All anti HIV-1 positive patients had elevated ACA levels in 1983; normal values were found in 9 patients in 1987. Yet, these changes were not significant (p >0.05). ACA levels were significantly higher in HIV-1 infected patients than in those without anti HIV-1 antibodies (p <0.05). There was no difference of ACA levels between the two anti HIV-1 positive patient groups, be it in 1983 or be it in 1987 (p >0.05). There was no correlation of ACA levels with serum IgG concentrations, CD4+ lymphocytes, or the consumption of factor VIII concentrates.


Sign in / Sign up

Export Citation Format

Share Document